Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Treatment of Luminal Advanced Breast Cancer (MULAN)
NCT04355858Phase 2Unknown
- Sponsor
- Fudan University
- Start
- May 2020
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR7390, famitinib, fluzoparib, dalpiciclib, pyrotinib and 4 more in breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
SHR7390famitinibfluzoparibdalpiciclibpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04355858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355858.